Company intelligence / Profile preview

Biotheryx

San Diego, California, United Statesbiotheryx.com ↗

Ownership: Private
Employees: ~32
Development stage: Phase 1

Overview

BTX-9341, a first-in-class bifunctional degrader of CDK4/6, began Phase 1 clinical trial in Q3 2024 for HR+/HER2- breast cancer. The first patient was dosed on July 17, 2024. The trial is evaluating BTX-9341 as a monotherapy and in combination with fulvestrant for patients with advanced and/or metastatic HR+/HER2- breast cancer who have previously received CDK4/6 inhibitor therapy.

Therapeutic areas: OncologyImmunology
Modalities: Protein degradersbifunctional degradersmolecular gluessmall molecules
Industry: Biotech

Drug pipeline

7 assets

BTX-9341

6 more assets in the full pipeline.

Partnerships

Incyte (research collaboration and license agreement to discover molecular glue degraders for multiple historically undruggable novel oncology targets)

Beyond the preview

Go deeper on Biotheryx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biotheryx.